MedTrace Logo

Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening

NCT04498052 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1855

Last updated 2025-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to increase appropriate low-dose computed tomography (LDCT) lung cancer screening through the development and wide dissemination of patient-centered clinical decision support (CDS) tools that (1) are integrated with the electronic health record (EHR) and clinical workflows, (2) prompt for shared decision making (SDM) when patients meet screening criteria, and (3) enable effective SDM using individually-tailored information on the potential benefits and harms of screening. The study will promote standard of care that is endorsed by the Centers for Medicare \& Medicaid Services (CMS) and the US Preventive Services Task Force (USPSTF).

Conditions

  • Early Detection of Cancer
  • Lung Neoplasms

Interventions

OTHER

EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening

The intervention will consist of the following core items: In period 1: * An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+. * Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's "Health Maintenance" module as well as an EHR-integrated "Disease Manager" system for disease management and health maintenance. In period 2: \- Same as period 1 + simple patient reminders in the patient portal. Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption.

Sponsors & Collaborators

Principal Investigators

  • Kensaku Kawamoto, MD, PhD, MHS · University of Utah

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-23
Primary Completion
2022-04-27
Completion
2024-12-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04498052 on ClinicalTrials.gov